Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas

Mina M. Gerges, MD,^{1,2} Kavelin Rumalla, BA,⁶ Saniya S. Godil, MD,^{1,3} Iyan Younus, BS,⁵ Walid Elshamy, MD,² Georgiana A. Dobri, MD,^{1,7} Ashutosh Kacker, MD,⁴ Abtin Tabaei, MD,⁴ Viay K. Anand, MD,⁴ and Theodore H. Schwartz, MD^{1,4}

Departments of ¹Neurosurgery, ⁴Otolaryngology, and ⁷Endocrinology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York; ⁵Weill Cornell Medical College, New York, New York; ²Department of Neurosurgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt; ³Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee; and ⁶Department of Biomedical and Health Informatics, University of Missouri–Kansas City School of Medicine, Kansas City, Missouri

OBJECTIVE Nonfunctioning pituitary adenomas are benign, slow-growing tumors. After gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and may ultimately require additional intervention. A greater understanding of long-term recurrence and progression rates following complete or partial resection and the need for further intervention will help clinicians provide meaningful counsel for their patients and assist data-driven decision-making.

METHODS The authors retrospectively analyzed their institutional database for patients undergoing endoscopic endonasal surgery (EES) for nonfunctioning pituitary macroadenomas (2003–2014). Only patients with follow-up of at least 5 years after surgery were included. Tumor volumes were measured on pre- and postoperative MRI. Tumor recurrence was defined as the presence of a 0.1-cm³ tumor volume after GTR, and tumor progression was defined as a 25.0% increase in residual tumor after STR.

RESULTS A total of 190 patients were included, with a mean age of 63.8 ± 13.2 years; 79 (41.6%) were female. The mean follow-up was 75.0 ± 18.0 months. GTR was achieved in 127 (66.8%) patients. In multivariate analysis, age ($p = 0.04$), preoperative tumor volume ($p = 0.03$), Knosp score ($p < 0.001$), and Ki-67 ($p = 0.03$) were significant predictors of STR. In patients with GTR, the probability of recurrence at 5 and 10 years was 3.9% and 4.7%, and the probability of requiring treatment for recurrence was 0.79% and 1.6%, respectively. In 63 patients who underwent STR, 6 (9.5%) received early postoperative radiation and did not experience progression, while the remaining 57 (90.5%) were observed. Of these, the probability of disease progression at 5 and 10 years was 21% and 24.5%, respectively, and the probability of requiring additional treatment for progression was 17.5% and 21%. Predictors of recurrence or progression in the entire group were Knosp score ($p < 0.001$) and elevated Ki-67 ($p = 0.03$). Significant predictors of progression after STR in those who did not receive early radiotherapy were cavernous sinus location ($p < 0.05$) and tumor size > 1.0 cm³ ($p = 0.005$).

CONCLUSIONS Following GTR for nonfunctioning pituitary adenomas, the 10-year chance of recurrence is low and the need for treatment even lower. After STR, although upfront radiation therapy may prevent progression, even without radiotherapy, the need for intervention at 10 years is only approximately 20% and a period of observation may be warranted to prevent unnecessary prophylactic radiation therapy. Tumor volume > 1 cm³, Knosp score ≥ 3 , and Ki-67 $\geq 3\%$ may be useful metrics to prompt closer follow-up or justify early prophylactic radiation therapy.

<https://thejns.org/doi/abs/10.3171/2019.11.JNS192457>

KEYWORDS endoscopic; long-term outcomes; non-hormone producing; follow-up; pituitary adenoma; transsphenoidal; macroadenoma; endonasal; pituitary surgery

NONFUNCTIONING pituitary adenomas are benign, generally slow-growing tumors known to have a great heterogeneity in clinical behavior, histopathological features, growth rates, and invasion into surrounding structures.³ These factors render the prediction of their

natural history quite challenging. Treatment is indicated to relieve symptoms of mass effect or to prevent such symptoms if significant growth is observed. Given the relatively low morbidity of transsphenoidal surgery, operative intervention is often the first line of therapy. Once surgery is

ABBREVIATIONS ACTH = adrenocorticotrophic hormone; EES = endoscopic endonasal surgery; FSH = follicle-stimulating hormone; GH = growth hormone; GTR = gross-total resection; IGF-1 = insulin-like growth factor-1; LH = luteinizing hormone; PRL = prolactin; STR = subtotal resection; TSH = thyroid-stimulating hormone.

SUBMITTED September 18, 2019. **ACCEPTED** November 20, 2019.

INCLUDE WHEN CITING Published online January 31, 2020; DOI: 10.3171/2019.11.JNS192457.

completed, either tumors are observed or, if significant residual tumor remains, patients may undergo radiation therapy to prevent further growth. A thorough understanding of the recurrence rates of completely resected tumors and the progression rates of subtotaly resected tumors is required to counsel patients on the frequency of postoperative imaging and the likelihood of requiring additional intervention in their remaining lifetime. These decisions should be derived from long-term data in large populations of patients with adequate follow-up.

Over the past 20 years, endoscopic endonasal surgery (EES) has grown in popularity for removing pituitary tumors, and short-term outcome studies have demonstrated higher rates of resection, particularly for larger macroadenomas with invasion into the adjacent parasellar compartments.³⁸ In theory, more radical debulking of large tumors and higher rates of gross-total resection (GTR) may impact long-term recurrence rates and the need for prophylactic radiation therapy or the frequency of postoperative imaging. In this paper, we present a large series of patients with nonfunctioning macroadenomas removed through EES and provide long-term outcome data for more than 5 years of follow-up. It is the general policy at Weill Cornell not to offer upfront radiation therapy unless there is regrowth of tumor, and thus some data on the natural history of subtotaly resected tumors are also presented. It is our hope that these findings will help guide clinicians with patient counseling and management.

Methods

Patient Population

All patients with nonfunctioning pituitary macroadenomas who underwent EES by our senior author (T.H.S.) between June 2003 and December 2014 were reviewed. IRB approval was obtained for this study. In order to provide a more accurate picture of the long-term outcome, only patients with ≥ 5 years of postoperative follow-up were included. Nonfunctioning pituitary adenomas were defined by 1) the presence of a sellar mass > 1 cm in any dimension; and 2) the absence of elevated serum prolactin (PRL) > 200 ng/mL, growth hormone (GH), insulin-like growth factor-1 (IGF-1), cortisol, and adrenocorticotrophic hormone (ACTH), along with no clinical suspicion for Cushing disease.

Data Collection

A total of 190 patients met the inclusion criteria. Electronic medical records were reviewed and included preoperative and postoperative clinic visits, inpatient records, laboratory results, the operative report, and radiological images and reports. Preoperative data abstracted from medical records included demographic data, medical history, clinical examination, and endocrine status. All patients underwent a baseline preoperative pituitary panel that included serum cortisol, free thyroxine, thyroid-stimulating hormone (TSH), ACTH, GH, IGF-1, PRL, luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (in males), and estradiol (in females); if there was suspicion for Cushing disease, further biochemical evaluation was conducted. Preoperative radiological as-

essment included tumor volume (estimated according to the equation $(A \times B \times C)/2$ and extension and invasion into the suprasellar cistern (Hardy classification), cavernous sinus (Knosp classification), or sphenoid sinus.¹⁸

Perioperative outcomes (histology, complications, and extent of resection) and long-term outcomes (endocrine status, visual outcomes, and recurrence/progression rates) were also recorded. Diabetes insipidus was considered permanent if there was a need to continue desmopressin at the last follow-up. Extent of resection was determined as GTR or subtotal resection (STR) based on immediate postoperative MRI. Recurrence was defined as at least a 0.1-cm³ growth of adenoma after GTR. Progression was defined by more than a 25% increase in the volume of residual tumor after STR compared with its size on early postoperative images. Regression was considered as at least a 25% decrease in the volume during follow-up after STR.

Statistical Analysis

All data were analyzed using SPSS (version 26.0, IBM Corp.). A p value < 0.05 was considered statistically significant. Descriptive statistics were collected for all variables. Parametric data are given as mean $\pm$ SD and compared using an independent-samples t -test. Nominal (categorical) data were compared using the chi-square test. Multivariate logistic regression models were designed to attempt to identify predictors of extent of resection and recurrence/regression/progression. Variables with a minimum of 10 cases and $\alpha < 0.05$ in univariate analysis were included in multivariate models. For purposes of multivariate analysis, preoperative tumor size and Ki-67 were converted into nominal variables by percentiles, with tumor size converted to small (0–33rd percentile, < 3 cm), medium (34th–66th percentile, 3–8 cm), or large (67th–99th percentile, > 8 cm) and Ki-67 into low (0–2.9) or high (≥ 3), and Knosp score into low (1 or 2) or high (3 or 4).

Kaplan-Meier curves were created to calculate the probability of recurrence or progression, and the log-rank test was performed to compare the risk of tumor recurrence or progression based on the several variables listed above.

Results

Patient Demographics, Clinical Presentation, and Tumor Characteristics

Cases were drawn from a prospective database accrued between 2003 and 2014. During this time period, there were 235 EES procedures for resection of nonfunctioning pituitary adenomas. Of these patients, 190 had ≥ 5 years of follow-up with a mean of 73.7 ± 18.3 months and form the basis of this study. The mean age was 63.8 ± 13.2 years, and 41.6% ($n = 79$) of patients were female (Table 1). The most common presenting symptoms were visual complaints (62.4%), headaches (41.6%), and cranial nerve deficits (2.1%). There were 19 (10.0%) reoperations. The average tumor volume was 8.6 ± 11.8 cm³. Sphenoid sinus extension was present in 5.8% and suprasellar extension in 96.8%. Chiasmal compression was present in 86.8% and cavernous sinus invasion in 34.2% of patients. Suprasellar extension ($p = 0.001$) and chiasmal compression ($p =$

TABLE 1. Demographics, clinical presentation, tumor characteristics, and postoperative outcomes

	Value
Mean age, yrs	63.8 ± 13.2
Female sex	79 (41.6)
Clinical presentation	
Incidental	56 (29.5)
Symptomatic	134 (70.5)
Visual	119
Headache	79
Panhypopituitarism	19
CN deficit	4
Mean preop tumor size, cm ³	8.6 ± 11.8
Suprasellar extension	184 (96.8)
Chiasmal compression	165 (86.8)
Cavernous sinus invasion	65 (34.2)
Sphenoid sinus invasion	11 (5.8)
Hardy classification scale for suprasellar extension	
0	7 (3.7)
A	71 (37.4)
B	61 (32.1)
C	45 (23.7)
D	6 (3.2)
Knosp score	
1	13 (6.8)
2	20 (10.5)
3	20 (10.5)
4	12 (6.3)
Postop outcome	
Vision	
Stable	88 (46.3)
Improved	97 (51.1)
Worse	5 (2.6)
DI	16 (8.4)
Temporary	6 (3.2)
Permanent	10 (5.3)
Hematoma	2 (1.1)
CSF leak	6 (3.2)

CN = cranial nerve; DI = diabetes insipidus.

Values are presented as the number of patients (%) unless otherwise indicated. Mean values are presented as the mean ± SD.

0.02) were significantly more likely in primary than in the revision surgeries (Table 2). The Hardy classification and Knosp score are shown in Table 1.

Perioperative Outcomes

All patients underwent EES for their pituitary adenoma. Extended transsphenoidal approaches were used in 83 (43.7%) patients (transcavernous 21.1%, transplanum 35.8%, transclival 2.1%). Immunohistochemistry was positive for LH in 25.1%, FSH in 27.7%, ACTH in 8.4%, PRL in 7.3%, TSH in 3.1%, and GH in 2.6%. The mean Ki-67

TABLE 2. Comparison of demographics, postoperative outcome, and long-term follow-up between primary and revision cases

	Primary Cases (n = 171)	Revision Cases (n = 19)	p Value
Mean age, yrs	63.6 ± 13.2	65.4 ± 13.3	0.55
Sex			
Male	105 (61.4)	6 (31.6)	0.06
Female	66 (38.6)	13 (68.4)	
Preop clinical data			
Visual complaints	109 (63.7)	10 (52.6)	0.34
CN deficit	4 (2.3)	0	NA
Preop tumor characteristics			
Mean vol, cm ³	8.7 ± 10.6	8.5 ± 19.8	
Suprasellar extension	169 (98.8)	15 (78.9)	0.001
Chiasmal compression	151 (88.3)	14 (73.7)	0.02
Cavernous sinus invasion	58 (33.9)	7 (36.8)	0.79
Sphenoid sinus invasion	9 (5.3)	2 (10.5)	0.35
Postop outcome			
Vision			
Stable	74 (43.2)	14 (73.6)	0.03
Improved	92 (53.8)	5 (26.3)	
Worse	5 (2.9)	0	
DI	12 (7.0)	4 (21.1)	0.03
Postop endocrine			
Hypopituitarism	28 (16.4)	8 (42.1)	0.01
Hypogonadism	16 (9.4)	1 (5.3)	
Hypothyroidism	2 (1.2)	2 (10.5)	
Hypocortisolism	3 (1.8)	0	
Hematoma	2 (1.2)	0	NA
CSF leak	6 (3.5)	0	NA
Extent of resection			
GTR	116 (67.8)	11 (57.9)	0.38
STR	55 (32.2)	8 (42.1)	

NA = not applicable.

Values are presented as the number of patients (%) unless otherwise indicated. Mean values are presented as the mean ± SD.

was 2.57 ± 2.32 . Postoperative CSF leakage occurred in 6 (3.2%) patients and was successfully treated with a lumbar drain postoperatively in 5 patients; 1 (0.5%) patient required endoscopic exploration and repair. Surprisingly, all CSF leaks occurred following first-time operations and none after reoperations (Table 2). Postoperative hematoma requiring surgical evacuation occurred in 2 (1.1%) patients.

Visual symptoms improved in 97 (51.1%) patients while deterioration occurred in 5 (2.6%). The rate of visual improvement was significantly higher in first-time surgeries than in revisions (53.8% vs 26.3%, $p = 0.03$) (Table 2). A total of 10 (5.3%) patients developed new hypopituitarism after surgery, while the other 26 (13.7%) patients with postoperative hypopituitarism had endocrine dysfunction preoperatively (Table 3). Postoperative diabetes insipidus was observed in 16 cases (8.4%), more commonly after

TABLE 3. Perioperative endocrine status

	No. of Patients (%)				
	Preop	At Last Follow-Up	Improved	Stable	Worse
Hypopituitarism	19 (10.0)	36 (19.0)	2	17	0
Hypogonadism	23 (12.1)	17 (9.0)	4	13	6
Hypothyroidism	5 (2.6)	3 (1.6)	0	3	2
Hypocortisolism	3 (1.6)	3 (1.6)	1	2	0
Mixed	5 (2.6)	6 (3.1)	1	3	1
Normal function	135 (71.1)	117 (61.6)†	0	117	18*

* Postoperative dysfunction in 18 patients: 10 with panhypopituitarism, 6 with hypogonadism, 1 with hypocortisolism, and 1 with hypogonadism and hypothyroidism.

† Eight patients (4.2%) with preoperative endocrine dysfunction improved postoperatively.

reoperations (21.1% vs 7%, $p = 0.03$) (Table 2), resulting in permanent diabetes insipidus in only 10 (5.3%) patients (Table 1). Anterior pituitary dysfunction was seen more commonly in reoperations than in first-time surgeries ($p = 0.01$) (Table 2).

Extent of Resection

GTR was achieved in 127 (66.8%) patients and STR in 63 (33.2%) patients (Table 4). There was no significant difference in GTR rates between primary operations and reoperations (Table 2). In a univariate analysis, preoperative tumor size ($p = 0.002$), Knosp score ($p < 0.001$), cavernous sinus invasion ($p < 0.001$), sphenoid sinus invasion ($p = 0.03$), and Ki-67 ($p = 0.03$) were significant predictors of extent of resection (Table 5). The variables “cavernous sinus invasion” and “sphenoid sinus invasion”

TABLE 4. Extent of tumor resection and long-term follow-up status

	GTR	STR
No. of patients	127 (66.8)	63 (33.2)
Mean follow-up, mos	75.0 ± 18.0	73.8 ± 16.6
Upfront RT	0	6 (9.5)
Stable	121 (95.3)	43 (68.3)
Recurrence	6 (4.7)	NA
Progression	NA	14 (22.2)
Regression	NA	6 (9.5)
Mean time to recurrence or progression, mos	40.7 ± 33.3	47.8 ± 23.3
Recurrence or progression requiring intervention	2 (1.6)	12 (19.0)
Recurrence or progression management		
RT	1 (0.8)	9 (14.3)
Surgery + RT	1 (0.8)	3 (4.8)

RT = radiotherapy.

Values are presented as the number of patients (%) unless otherwise indicated. Mean values are presented as the mean ± SD.

TABLE 5. Univariate factors associated with extent of resection

	GTR	STR	p Value
Preop visual deficits	59.0	69.8	0.15
Mean preop tumor size, cm ³	6.5 ± 8.3	12.9 ± 15.9	0.004
Preop tumor size			0.002
Small (<3 cm ³)	77.8	22.2	
Medium (3–8 cm ³)	70.6	29.4	
Large (>8 cm ³)	48.1	51.9	
Knosp score			<0.001
Low (1 or 2)	96.1	54.0	
High (3 or 4)	3.9	46.0	
Suprasellar extension	97.6	95.2	0.4
Cavernous sinus invasion	19.7	63.5	<0.001
Sphenoid sinus invasion	3.1	11.1	0.03
GH	2.4	3.2	0.7
PRL	7.2	7.9	0.8
ACTH	8.8	7.9	0.8
TSH	2.4	4.9	0.4
Mean Ki-67	2.3	3.1	0.04
Ki-67			0.03
1–2.9%	40.5	31.8	
≥3%	18.9	36.5	

Values are presented as percentages unless otherwise indicated. Mean values are presented as the mean ± SD.

did not meet criteria (low sample size) for entry into the multivariate model. In multivariate analysis, statistically significant ($p < 0.05$) predictors of STR were age (OR 1.03 per year), large (top tercile, > 8 cm³) preoperative tumor size (OR 2.9), and Knosp score 3 or 4 (OR 15.1, reference score 1–2) (Table 6). Ki-67 was no longer a predictor

TABLE 6. Multivariate predictors of extent of resection

	OR	p Value
All		
Age	1.03	0.04
Preop tumor size		
Small (<3 cm ³)	Reference	
Medium (3–8 cm ³)	1.3	0.5
Large (>8 cm ³)	2.9	0.03
Knosp score	15.1	<0.001
Ki-67	1.09	0.4
w/ Knosp score omitted		
Age	1.03	0.07
Preop tumor size		
Small (<3 cm ³)	Reference	
Medium (3–8 cm ³)	1.4	0.4
Large (>8 cm ³)	4.7	<0.001
Ki-67	1.2	0.03
Knosp score	Omitted	Omitted

FIG. 1. Rates of recurrence following GTR or progression following STR (A) and rates of need for treatment following GTR versus STR (B).

of STR when included in the multivariate analysis due to colinear interaction with the Knosp score. In a separate model excluding the Knosp score, Ki-67 was a significant predictor of STR (OR 1.2 per additional 1 point, $p = 0.03$) (Table 6).

Recurrence or Progression of Disease

Of the 127 patients with GTR, radiographic recurrence was seen in 6 (4.7%) with an average follow-up duration of 75.0 ± 18.0 months. The mean time to recurrence was 41 ± 33.3 months. Among these patients, 4 were observed

FIG. 2. Serial MR images showing diminution in size of residual tumor after STR. **A–D:** Patient 1. Immediate postoperative sagittal (A) and coronal (B) MR images showing residual pituitary macroadenoma with some suprasellar extension. Follow-up sagittal (C) and coronal (D) MR images obtained 75 months after resection, showing cavity shrinkage and regression of the residual tumor. **E–H:** Patient 2. Sagittal (E) and coronal (F) MR images obtained at the 3-month follow-up, showing suprasellar residual surrounding the internal carotid artery. Follow-up sagittal (G) and coronal (H) MR images obtained 36 months after endoscopic transsphenoidal resection, showing regression of the residual tumor.

TABLE 7. Univariate and multivariate analyses of factors associated with recurrence or progression for the entire cohort

	Univariate Analysis		Multivariate Analysis	
	Recurrence/Progression, %	p Value	OR	p Value
All patients (n = 190)	13.7			
Preop visual deficit		0.2		0.68
No	9.9		Reference	
Yes	16.0		1.2	
Preop tumor size		0.09		0.38
Lower 2/3 tercile	10.9		Reference	
Upper 1/3 tercile (>8 cm ³)	20.4		1.6	
Knosp score		<0.001		0.01
1–2	9.0		Reference	
3–4	35.3		3.7	
Ki-67		0.03		0.13
0–2.9% (lower 50th percentile)	7.5		Reference	
≥3% (upper 50th percentile)	18.2		2.2	
Revision surgery		0.09		0.06
No	12.3		Reference	
Yes	26.3		3.3	
IHC staining				
TSH positive	20.1	0.09	3.1	0.08
ACTH positive	9.5	0.8		
PRL positive	10.8	0.6		
GH positive	15	0.5		

IHC = immunohistochemistry.

without further treatment, 1 underwent repeat EES and radiosurgery, and 1 received radiosurgery only (Table 4). Thus, only 1.6% (2/127) required treatment. Following GTR, the 5- and 10-year probability of recurrence was 3.9% and 4.7% (Fig. 1), and the probability of requiring additional treatment for recurrence was 0.79% and 1.6% (Fig. 1), respectively.

In the 63 patients with STR, 43 (68.3%) were observed without any further growth, 6 (9.5%) received upfront prophylactic radiosurgery, 6 (9.5%) patients had radiographic tumor regression (Fig. 2), and 14 (22.2%) had radiographic progression. The average follow-up duration was 73.8 ± 16.6 months, and the mean time to progression was 48 ± 23.3 months. The average size of the residual tumors that received radiation therapy was 1.8 cm³ compared with 0.8 cm³ for those that were observed. The 6 patients who received upfront prophylactic radiation therapy to the residual tumor did not experience progression. Of the 14 patients with progression, 2 had minimal progression that did not require treatment, whereas 12 patients required treatment; 3 underwent revision surgery and radiation therapy, whereas 9 had radiotherapy only (Table 4). Hence, of the 63 patients with STR only, 18 (28.6%) required additional treatment other than observation (which includes the 6 who had early prophylactic radiation). Following STR (including the 6 patients who received early prophylactic postoperative radiation), the 5- and 10-year probability of disease progression was 19.1% and 22.2%, respectively,

and the probability of receiving treatment after STR (including early prophylactic radiotherapy) was 25.4% and 28.6%, respectively (Fig. 1).

For the entire cohort, univariate predictors for recurrence or progression were high (3 or 4) Knosp score ($p < 0.001$) and high ($\geq 3\%$) Ki-67 ($p = 0.03$) (Table 5). Tumor size > 8 cm³ and revision surgery also trended toward significance ($p = 0.09$) (Table 7). Kaplan-Meier curves showing the impact of these variables on recurrence and/or progression are shown in Fig. 3. In multivariate analysis, Knosp score ($p = 0.01$) was the only significant predictor for recurrence or progression, but revision surgery trended toward significance ($p = 0.06$) (Table 7).

We found that only TSH-stained adenomas trended toward an increase in recurrence or progression in univariate analysis ($p = 0.09$) and in multivariate analysis ($p = 0.08$) (Table 7), whereas other immunohistochemical staining, including ACTH-stained adenomas, did not show such a predilection.

Disease Progression in Patients Following STR Excluding Those Who Received Early Radiotherapy

Following STR, excluding patients who had early prophylactic radiation therapy, the 5- and 10-year probability of disease progression was 21% and 24.5% and the probability of requiring additional treatment for progression was 17.5% and 21%, respectively. In subgroup analysis of

FIG. 3. Predictors of recurrence/progression-free survival in the entire cohort (A–C) and predictors of progression-free survival after STR after excluding the patients with upfront prophylactic radiotherapy (D–F).

these STR patients who did not receive early prophylactic radiation therapy, factors associated with progression were postoperative residual size $> 1 \text{ cm}^3$ (50% vs 14.3%, $p = 0.005$), residual mass located laterally (cavernous sinus or middle cranial fossa) versus midline (sellar, suprasellar) (31.4% vs 10.7%, $p = 0.049$), and revision surgery versus primary surgery (50% vs 18.2%, $p = 0.04$) (Table 8). In multivariate analysis, these factors trended toward significance (Table 8). Kaplan-Meier curves showing the impact of these variables on progression are shown in Fig. 3.

Discussion

This study demonstrates that the 10-year recurrence rate following EES GTR for nonfunctioning pituitary adenomas

is quite low ($< 5\%$). Moreover, the need for treatment at 10 years is even lower, roughly 1.6%. These data are not only lower than most of the long-term data previously published in the literature (Table 9) but also useful in counseling patients and reassuring them once GTR has been established on postoperative imaging. Moreover, if STR is achieved, most tumors can be observed and will not grow; in fact, some may regress. The need for intervention in this scenario is roughly 30%, and most of these interventions occur within 5 years in patients with larger tumors ($> 1 \text{ cm}^3$) invading the cavernous sinus with $\text{Ki-67} \geq 3\%$. These data can be used to potentially avoid unnecessary prophylactic radiation therapy for patients with residual tumors and also guide clinicians to direct certain patients to early prophylactic radiation therapy who are at high risk of progression.

TABLE 8. Univariate and multivariate factors associated with progression following STR, excluding patients who received early prophylactic radiation therapy

	Univariate Analysis		Multivariate Analysis	
	Progression	p Value	OR	p Value
Total patients (n = 63)				
No. w/ progression (%)	14 (22.2)			
Postop residual				0.07
<1.0 cm ³	14.3	0.005	Reference	
>1.0 cm ³	50.0		2.9	
Residual site		0.049		0.10
Midline (sellar/suprasellar)	10.7		Reference	
Lateral (cavernous sinus)	31.4		3.7	
Ki-67		0.28		
0–2.9% (lower 50th percentile)	14.3			
≥3% (upper 50th percentile)	26.2			
Revision surgery		0.04		0.08
No	18.2		Reference	
Yes	50.0		5.3	

Recurrence following complete GTR of non–hormone-producing pituitary adenomas is likely due to microscopic cellular invasion into surrounding dura that is not visualized radiologically or intraoperatively. Meij et al.²⁷ found such microscopic invasion in up to 46% of dural specimens, particularly in larger tumors. In studies with limited follow-up, recurrence rates of 0% have been reported, but these studies lack adequate long-term data.^{10,11,21,32} The rate of recurrence after microscopic transsphenoidal surgery with long-term follow-up has been reported to range anywhere from 6% to 20%.¹⁰ For instance, Dekkers et al. and Chang et al. reported rates of 19% and 9%, respectively, according to the 10-year Kaplan-Meier estimate.^{2,4} Long-term outcomes following EES for pituitary adenomas have shown recurrence rates up to 10.7%–25.0% (Table 9).^{3,22,37} Dallapiazza et al. and Levy et al. reported rates of 20% and 25%, respectively, according to the 10-year Kaplan-Meier estimate. Our study, which established extent of resection with postoperative MRI, revealed a much lower 10-year recurrence rate of 4.7%. These results support the efficacy of achieving complete GTR using extended endoscopic approaches and support our earlier findings on extent of resection in both first-time operations and reoperations using shorter-term outcome data.^{7,13,19,29,30}

Reports of progression rates after STR are much more variable due to heterogeneity of inclusion criteria, tumor characteristics, definitions of progression, and duration of follow-up.¹⁵ In a series of 80 patients, Dallapiazza et al.³ reported a progression rate of 52% with a mean follow-up of 72 months. On the other hand, Seltzer et al.³⁷ reported a progression rate of 8.3% in a group of 24 patients with a mean follow-up of 61 months. Paluzzi et al.³² reported a progression rate of 63.9% with a mean follow-up of 3.1 years. The majority of long-term studies of microscopic transsphenoidal surgery reported progression rates less than 50% (Table 9). These rates do not include those for patients who received early radiation therapy following

STR. The reported 10-year progression rates following EES for pituitary adenomas were 79% (Dallapiazza et al.³) and 60% (Levy et al.²²), respectively. In our cohort, we report a lower 10-year progression rate of 22% for the entire cohort, including a small subgroup that received prophylactic radiation therapy, or 24.5% for patients who did not receive early radiotherapy. The lower rates of recurrence even after STR in this series might be attributed to several factors. Many of our STR patients had a very small amount of residual tumor (< 1 cm³), and, as we have shown that smaller residuals are less likely to recur, our recurrence rates might be lower than previously published. In addition, the delivery of early postoperative radiation therapy is generally not randomized and thus there may be variable amounts of selection bias in different series regarding who received early radiation therapy and who was followed expectantly. Even in our series, the average tumor volume in STR patients who underwent radiation therapy early was slightly larger than that in those who were observed. Resolution of this ambiguity would require that all patients who receive STR be deprived of early radiation and followed closely, which may not be in the best interest of the patients since there is clearly a subgroup with a higher risk of recurrence, namely those with larger residual tumors, higher Ki-67, and cavernous sinus invasion.

Identification of clinical, radiological, and histopathological factors associated with the degree of resection and recurrence/progression is important for patient counseling and surgical decision-making. In our series, STR was more likely for tumors of larger size, significant cavernous sinus invasion (per Knosp score), and elevated Ki-67. Furthermore, we found that tumor invasiveness (high Knosp score and Ki-67) and larger residual tumor (> 1 cm³) were also associated with a higher risk of progression. These findings are supported by prior literature. Dallapiazza et al.³ also identified cavernous sinus invasion (Knosp scoring) as a predictor of tumor recurrence. Other authors have

TABLE 9. Previous literature on extent of resection and recurrence following surgery for non-hormone-producing adenomas

Authors & Year	No. of Pts, Tumor Type	% Pts w/ GTR	Follow-Up (mos)	Early Adjuvant RT	Outcome: R Post-GTR; P Post-STR	Time to R or P (mos), RFS or PFS	Factors Predictive of R or P
Gondim et al., 2010	93	75.2%	61.5	No RT	R 0%; P ND	ND	ND
Koutourousiou et al., 2013	54	20.4%	37.9	ND	R 0%; P 14.8%	ND	ND
Berkmann et al., 2014	85	66 %	67.2	No RT	R 7%; P 64%	43.2	ND
Paluzzi et al., 2014	359	66.5%	37.3	No RT	R 0%; P 63.9%	ND	ND
Dallapiazza et al., 2015	80	71%	72	RT in 4 pts w/ P in 1	R 12%; P 52%	RFS at 10 yrs 80%; PFS at 10 yrs 21%	Knosp score
Ferrelli et al., 2015	56, CSI	30.3%	61	RT in 1 pt only	R 0%; P 17.9%	ND	ND
Kuo et al., 2016	39, giant	21%	72.9	RT in 20 pts from 30 pts w/ STR	R 0%; P 3.3%	ND	ND
Levy et al., 2018	132	18.9%	91.2	No RT	R 10.7%; P 35.5%	RFS at 10 yrs 75%; PFS at 10 yrs 40%	Postop residual beyond the sella; longer follow-up
Lv et al., 2018	270, FPA+NFPA	71.1%	44	No RT	R 25.0%; P 37.2%	ND	Ki-67, tumor size, STR, IHC
Seltzer et al., 2019	51, incidental	53%	61	No RT	R 11.1%; P 8.3%	104	
						45	
Elishazly et al., 2018	51, giant	44%	41	RT in 6 pts w/o P	R & P 12%	ND	ND
Lillehei et al., 1998	32	ND	66	No RT	R & P 6%	18–24	ND
Zhang et al., 1999	208	70%	45.6	ND	R 6.4%	ND	ND
Turner et al., 1999	65	ND	76	No RT	R & P 32%	RFS: at 5 yrs 82%, at 10 yrs 65%	
Woollons et al., 2000	50	18%	67	RT	R 0%; P 32%	31	No RT, incomplete removal
	22	50%	58	No RT	R 18%; P 72.7%	34.8	
Soto-Ares et al., 2002	51	33.3%	67.7	No RT	R 0%; P 38.2%	PFS at 5 yrs 70%	STR
Greenman et al., 2003	122	24%	51	Total (14 RT)	R 20%; P 52.5%	61	Knosp score, suprasellar residual
	108	27.8%		No RT		27.3	
Park et al., 2004	168	80%	45	No RT	R & P 15.5%	RFS: at 5 yrs 84.8%, at 10 yrs 49.5%	Invasiveness, younger age,
	70	20%	68	RT	R & P 1.4%	RFS: at 5 yrs 97.7%, at 10 yrs 97.7%	female, STR, RT
Dekkers et al., 2006	97	27.8%	72	6 upfront	R 0%; P 12.8%	RFS: at 5 yrs 94%, at 10 yrs 81%; PFS: at 5 yrs 92%, at 10 yrs 74%	Follow-up duration
Ferrante et al., 2006	295	36%	68	Total no. of pts	R 19.2%; P 58.4%		ND
	150	48.7%	112	No RT			
Chang et al., 2008	663	46%	101	ND	R 6.2%; P 12.4%	RFS: at 5 yrs 96%, at 10 yrs 91%; PFS: at 5 yrs 72%, at 10 yrs 55%	STR & no RT, Knosp score
Losa et al., 2008	491	64%	53	Excluded old age & pt refusal of RT	R & P 19%	RFS at 5 yrs 87.1%; PFS at 5 yrs 68.3%; PFS at 5 yrs in pts w/o RT 39.2%	Only no upfront RT
O'Sullivan et al., 2009	159	16.4%	68	No RT	R 0%; P 33.5%	PFS: at 5 yrs 24.4%, at 10 yrs 51.5%	Extrasellar residual, younger age
Present study	190	66.8%	75	RT in 6 pts	R 4.7%; P 22.2%	RFS at 10 yrs 95.3%; PFS at 10 yrs 78.8%	Ki-67, Knosp score

CSI = cavernous sinus invasion; FPA = functioning pituitary adenoma; ND = not defined; NFPA = nonfunctioning pituitary adenoma; P = progression; PFS = progression-free survival; pt = patient; R = recurrence; RFS = recurrence-free survival; RPS = recurrence- and progression-free survival.

also demonstrated progression rates of up to 17% for residual tumor in the cavernous sinus.⁹ Lv et al. identified tumor volume and the size of the residual as predictors of progression.²⁶ Similarly, macroadenomas, compared with microadenomas, have demonstrated increased incidence of regrowth.^{15,17,28,42}

The optimal timing of radiation therapy for residual tumors remains unclear because of the uncertainty of the growth rate of these tumors. Although some authors have advocated early radiotherapy for residual endocrine-inactive adenomas, the risk of delayed pituitary failure after radiation is high, with the majority of patients developing new endocrinopathy after 5–10 years.³⁴ Sadik et al. reported a hypopituitarism rate of 22% in an early radiotherapy cohort monitored for a mean of 40 months.³⁶ In a long-term study by Höybye et al., the rate was 72% with a mean follow-up of 17 years.¹⁴

Park et al.³³ studied the use of early radiation treatment versus expectant management for residual nonfunctioning adenomas. They found only a 10-year 2.3% recurrence rate with early treatment compared with a 50% rate of tumor progression if tumors were followed up clinically without radiation treatment. Upfront radiotherapy is recommended for incurable functioning adenomas and after reoperation for recurrent adenomas.¹¹ Our study indicates that while early radiation therapy likely reduces the risk of progression, the majority of patients can be observed without intervention. Such a policy would significantly reduce the rate of treatment-related iatrogenic hypopituitarism. In our series, the rate of progression was higher in tumors invading the cavernous sinus, with a tumor volume > 1 cm³, and with increased Ki-67. Therefore, the decision should be tailored individually according to patient age, residual tumor in proximity to the optic apparatus, hormonal status, and predictors of recurrence.⁶

In 2004, the WHO created a class of adenomas called “atypical” that are characterized by increased mitotic index, elevated Ki-67, and high p53 immunoactivity.⁵ These tumors were believed to have a higher growth rate and a more aggressive natural history and tended to occur in younger patients and in hormone-producing tumors and have a higher recurrence rate³⁵ after treatment. In 2013, a French collaborative study of prognostic factors of pituitary tumors introduced invasiveness as a criterion predicting more aggressive growth and recurrence.⁴⁰ This classification has been criticized since it appeared to be based on the assumption that invasive tumors are hardly resected.¹⁶ Yet, as we have shown, using expanded endonasal techniques, many of these invasive tumors can be completely resected with minimal or no residual.^{7,13,19,29,30} Nevertheless, in 2017 the term “atypical adenoma” was abandoned by the WHO due to a lack of adequate data to support this unique classification.²⁴ While many prior studies of aggressiveness have lumped hormone-producing and non-hormone-producing tumors together, this current series examines uniquely non-hormone-producing tumors and utilizes an aggressive expanded endonasal approach to maximize extent of resection. We confirm that invasiveness, size, and elevated Ki-67 are all predictors of STR and/or recurrence after surgery. Since the diagnosis of a more aggressive subtype of non-hormone-producing

adenoma is a postoperative diagnosis, these criteria cannot be used to guide initial therapy but rather postoperative management. For this reason, we have limited our recommendations to use these criteria to make recommendations regarding which patients might benefit from early prophylactic radiation therapy and which patients can be observed with little risk of eventual intervention.

Limitations

The present analysis is drawn from a retrospective cohort analysis and, thus, cannot be utilized to establish causality between risk factors and outcomes. Inherent to a retrospective study design, our data collection was limited by the accuracy and completeness of the electronic medical record. Our study was the largest series to date detailing long-term outcomes following EES for pituitary adenomas. However, analyses aimed at identifying predictors of recurrence and progression were limited by sample size of the subcohorts. We encourage the design of a multicenter prospective study to further study long-term outcomes and predictive analytics in patients undergoing EES for pituitary adenomas.³²

Conclusions

After GTR for nonfunctioning pituitary adenomas, the 10-year chance of recurrence is low and the need for treatment even lower. After STR, although upfront radiation therapy may prevent progression, even without it the need for intervention at 10 years is only approximately 20%, and a period of observation may be warranted to prevent unnecessary prophylactic radiation therapy. Tumor volume > 1 cm³, Knosp score ≥ 3, and Ki-67 ≥ 3% may be useful metrics to prompt closer follow-up or justify early prophylactic radiation therapy.

References

1. Berkman S, Schlaffer S, Nimsky C, Fahlbusch R, Buchfelder M: Follow-up and long-term outcome of nonfunctioning pituitary adenoma operated by transsphenoidal surgery with intraoperative high-field magnetic resonance imaging. *Acta Neurochir (Wien)* **156**:2233–2243, 2014
2. Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, et al: Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. *J Neurosurg* **108**:736–745, 2008
3. Dallapiazza RF, Grober Y, Starke RM, Laws ER Jr, Jane JA Jr: Long-term results of endonasal endoscopic transsphenoidal resection of nonfunctioning pituitary macroadenomas. *Neurosurgery* **76**:42–53, 2015
4. Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA, et al: Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. *J Clin Endocrinol Metab* **91**:1796–1801, 2006
5. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): **Pathology and Genetics of Tumours of Endocrine Organs: World Health Organization Classification of Tumours**, ed 3. Oxford: Oxford University Press, 2004, Vol 8
6. Elshazly K, Kshetry VR, Farrell CJ, Nyquist G, Rosen M, Evans JJ: Clinical outcomes after endoscopic endonasal resection of giant pituitary adenomas. *World Neurosurg* **114**:e447–e456, 2018
7. Esquenazi Y, Essayed WI, Singh H, Mauer E, Ahmed M, Christos PJ, et al: Endoscopic endonasal versus microscopical

- transsphenoidal surgery for recurrent and/or residual pituitary adenomas. **World Neurosurg** 101:186–195, 2017
8. Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, et al: Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. **Eur J Endocrinol** 155:823–829, 2006
 9. Ferrelli F, Turri-Zanoni M, Canevari FR, Battaglia P, Bignami M, Castelnovo P, et al: Endoscopic endonasal management of non-functioning pituitary adenomas with cavernous sinus invasion: a 10-year experience. **Rhinology** 53:308–316, 2015
 10. Gondim JA, Almeida JP, Albuquerque LA, Schops M, Gomes E, Ferraz T, et al: Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients. **Pituitary** 14:174–183, 2011
 11. Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, et al: Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. **Pituitary** 13:68–77, 2010
 12. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N: Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. **Clin Endocrinol (Oxf)** 58:763–769, 2003
 13. Hofstetter CP, Nanaszko MJ, Mubita LL, Tsiouris J, Anand VK, Schwartz TH: Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery. **Pituitary** 15:450–463, 2012
 14. Höybye C, Grenbäck E, Rahn T, Degerblad M, Thorén M, Hulting AL: Adrenocorticotrophic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. **Neurosurgery** 49:284–292, 2001
 15. Iglesias P, Arcano K, Triviño V, García-Sancho P, Díez JJ, Cordido F, et al: Non-functioning pituitary adenoma underwent surgery: a multicenter retrospective study over the last four decades (1977–2015). **Eur J Intern Med** 41:62–67, 2017
 16. Inoshita N, Nishioka H: The 2017 WHO classification of pituitary adenoma: overview and comments. **Brain Tumor Pathol** 35:51–56, 2018
 17. Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, et al: Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. **Neurosurgery** 71:296–304, 2012
 18. Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. **Neurosurgery** 33:610–618, 1993
 19. Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH: Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. **Pituitary** 15:150–159, 2012
 20. Koutourousiou M, Gardner PA, Fernandez-Miranda JC, Paluzzi A, Wang EW, Snyderman CH: Endoscopic endonasal surgery for giant pituitary adenomas: advantages and limitations. **J Neurosurg** 118:621–631, 2013
 21. Kuo CH, Yen YS, Wu JC, Chang PY, Chang HK, Tu TH, et al: Primary endoscopic transnasal transsphenoidal surgery for giant pituitary adenoma. **World Neurosurg** 91:121–128, 2016
 22. Levy MJ, Robertson IJ, Khalk N, Vitello S, Reddy N, Bhake R, et al: Long-term follow-up of a large prospective cohort of patients with nonfunctioning pituitary adenomas: the outcome of a conservative management policy. **Clin Endocrinol (Oxf)** 89:354–359, 2018
 23. Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC: Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. **Neurosurgery** 43:432–439, 1998
 24. Lopes MBS: The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. **Acta Neuropathol** 134:521–535, 2017
 25. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, et al: Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. **J Neurosurg** 108:525–532, 2008
 26. Lv L, Yin S, Zhou P, Hu Y, Chen C, Ma W, et al: Clinical and pathologic characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. **World Neurosurg** 118:e428–e435, 2018
 27. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr: The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. **J Neurosurg** 96:195–208, 2002
 28. Molitch ME: Pituitary tumours: pituitary incidentalomas. **Best Pract Res Clin Endocrinol Metab** 23:667–675, 2009
 29. Muskens IS, Zamanipoor Najafabadi AH, Briceno V, Lamba N, Senders JT, van Furth WR, et al: Visual outcomes after endoscopic endonasal pituitary adenoma resection: a systematic review and meta-analysis. **Pituitary** 20:539–552, 2017
 30. Negm HM, Al-Mahfoudh R, Pai M, Singh H, Cohen S, Dhandapani S, et al: Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas. **J Neurosurg** 127:397–408, 2017
 31. O'Sullivan EP, Woods C, Glynn N, Behan LA, Crowley R, O'Kelly P, et al: The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. **Clin Endocrinol (Oxf)** 71:709–714, 2009
 32. Paluzzi A, Fernandez-Miranda JC, Tonya Steffko S, Challinor S, Snyderman CH, Gardner PA: Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. **Pituitary** 17:307–319, 2014
 33. Park P, Chandler WF, Barkan AL, Orrego JJ, Cowan JA, Griffith KA, et al: The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. **Neurosurgery** 55:100–107, 2004
 34. Pomeranec IJ, Dallapiazza RF, Xu Z, Jane JA Jr, Sheehan JP: Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. **J Neurosurg** 125:202–212, 2016
 35. Rutkowski MJ, Alward RM, Chen R, Wagner J, Jahangiri A, Southwell DG, et al: Atypical pituitary adenoma: a clinicopathologic case series. **J Neurosurg** 128:1058–1065, 2018
 36. Sadik ZHA, Voormolen EHJ, Depauw PRAM, Burhani B, Nieuwlaet WA, Verheul J, et al: Treatment of nonfunctional pituitary adenoma postoperative remnants: adjuvant or delayed Gamma Knife radiosurgery? **World Neurosurg** 100:361–368, 2017
 37. Seltzer J, Wedemeyer MA, Bonney PA, Carmichael JD, Weiss M, Zada G: Outcomes following transsphenoidal surgical management of incidental pituitary adenomas: a series of 52 patients over a 17-year period. **J Neurosurg** 130:1584–1592, 2019
 38. Smith ML, Patel SK, Choudhry OJ, Eloy JA, Liu JK: Evolution of a microsurgical to endoscopic practice for treatment of pituitary tumors and skull base lesions: importance of multidisciplinary team approach and learning curve. **J Neurol Surg B** 73:A191, 2012
 39. Soto-Ares G, Cortet-Rudelli C, Assaker R, Boulinguez A, Dubest C, Dewailly D, et al: MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. **Eur J Endocrinol** 146:179–186, 2002
 40. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al: A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control

- study of 410 patients with 8 years post-operative follow-up. **Acta Neuropathol** **126**:123–135, 2013
41. Turner HE, Stratton IM, Byrne JV, Adams CBT, Wass JAH: Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation—a follow-up study. **Clin Endocrinol (Oxf)** **51**:281–284, 1999
 42. van Varsseveld NC, Bisschop PH, Biermasz NR, Pereira AM, Fliers E, Drent ML: A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. **Clin Endocrinol (Oxf)** **80**:395–402, 2014
 43. Woollons AC, Hunn MK, Rajapakse YR, Toomath R, Hamilton DA, Conaglen JV, et al: Non-functioning pituitary adenomas: indications for postoperative radiotherapy. **Clin Endocrinol (Oxf)** **53**:713–717, 2000
 44. Zhang X, Fei Z, Zhang J, Fu L, Zhang Z, Liu W, et al: Management of nonfunctioning pituitary adenomas with suprasellar extensions by transsphenoidal microsurgery. **Surg Neurol** **52**:380–385, 1999

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: Schwartz, Gerges, Rumalla, Younus, Elshamy, Dobri. Acquisition of data: Schwartz, Gerges, Godil, Younus, Kacker, Tabae, Anand. Analysis and interpretation of data: Gerges, Godil, Younus, Dobri, Kacker, Tabae, Anand. Drafting the article: Gerges, Rumalla, Younus, Dobri, Kacker, Tabae, Anand. Critically revising the article: Gerges, Rumalla, Godil, Dobri, Kacker, Anand. Reviewed submitted version of manuscript: Schwartz, Gerges, Godil, Kacker, Anand. Approved the final version of the manuscript on behalf of all authors: Schwartz. Statistical analysis: Gerges, Rumalla, Godil, Dobri, Tabae. Administrative/technical/material support: Gerges, Tabae. Study supervision: Schwartz, Gerges, Rumalla, Godil, Younus, Elshamy.

Correspondence

Theodore H. Schwartz: Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY. schwarh@med.cornell.edu.